Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Waterways Polluted With Antibiotics, Antimicrobials And Antifungals
Antibiotics, antimicrobials and antifungals are seeping into the waterways of North America, Europe and East Asia, according to an investigation published in the peer-reviewed journal Environmental Health Perspectives (EHP). Authored by Université de Montréal and Environment Canada researchers, the review found that consumption of anti-infectives for human and agriculture use contributes to their release into the environment and even into drinking water.
generic viagra online
Shedding Light On DNA Mechanisms
By manipulating individual atoms in DNA and forming unique molecules, a Georgia State University researcher hopes to open new avenues in research towards better understanding the mechanisms of DNA replication and transcription, and perhaps leading to new treatments for diseases.
News of the day
Branded Surgery Is Not Always The "Quick Fix" It Is Advertised To Be
Have you seen the commercial for in-office procedures that will make your face wrinkle-free or sculpt your stomach, with no downtime and no scars? Lifestyle Lift, Lunchtime Lift, Thread-Tox, and Smart-Lipo, are just a few of the brand-name surgical procedures being marketed to the public as a cosmetic quick fix with a clever name.
Health Insurance

Mylan Receives FDA Approval For Generic Version Of Prostate Cancer Treatment Casodex(R)

Mylan Inc. (Nasdaq: MYL) announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Bicalutamide Tablets, 50 mg. Bicalutamide Tablets are the generic version of AstraZeneca"s prostate cancer treatment Casodex(R), which had total U.S. sales of approximately $322 million for the 12 months ending March 31 for the same strength, according to IMS Health. Mylan has begun to ship this product. Currently, Mylan has 118 ANDAs pending FDA approval representing $82.8 billion in annual brand sales, according to IMS Health. Thirty-five of these pending ANDAs are potential first-to-file opportunities, representing $16.7 billion in annual brand sales, according to IMS Health. Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generics and specialty pharmaceutical companies in the world. The company maintains one of the industry"s broadest -- and highest quality -- product portfolios, supported by a robust product pipeline; owns a controlling interest in the world"s third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. Mylan Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009